Global Ischemia Reperfusion Market Insights Forecasts to 2030
- The Global Ischemia Reperfusion Injury Market Size was valued at USD 2.26 Billion in 2021.
- The Market is Growing at a CAGR of 3.7% from 2022 to 2030.
- The Worldwide Ischemia Reperfusion Injury Market Size is expected to reach USD 3.15 Billion by 2030.
- Asia Pacific is expected To Grow the fastest during the forecast period.
Get more details on this report -
The Global Ischemia Reperfusion Injury Market Size is expected to reach USD 3.15 Billion by 2030, at a CAGR of 3.7% during the forecast period 2022 to 2030. The rising number of tissue damaged cases around the world is anticipated to drive the growth of the Global Ischemia Reperfusion Injury Market.
Ischemia-reperfusion injury (IRI) is occurring when blood flow to an area of tissue is blocked (ischemia) and subsequently restored (reperfusion). This could emerge during situations such as heart attack, stroke, surgery, organ transplantation, and traumatic injury where a blood vessel is temporarily blocked and then reopened. IRI therapeutics aim to reduce inflammation, promoting tissue repair, and protecting against oxidative stress in order to avoid or mitigate this damage. Anti-inflammatory drugs, antioxidants, stem cell therapies, and gene therapies are some of the potential therapies for IRI treatment. For instance, according to the National Institutes of Health, the burden of cardiovascular diseases (CVDs) such as stroke and myocardial infection is increasing rapidly at a global level. This would, in turn, rises the number of patients with ischemia-reperfusion injury disorder. The conditions reduce ATP production and thus inactivate ion exchange channels.
This research report categorizes the global ischemia reperfusion injury market based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global ischemia reperfusion injury market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segments of the global ischemia reperfusion injury market. Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market.
Global Ischemia Reperfusion Injury Market Report Coverage
|Market Size in 2021:||USD 2.26 Billion|
|Forecast Period 2021-2030 CAGR:||3.7%|
|2030 Value Projection:||USD 3.15 Billion|
|Historical Data for:||2017-2020|
|No. of Pages:||200|
|Tables, Charts & Figures:||123|
|Segments covered:||By Injury, By End Users, By Region, and COVID-19 Impact Analysis|
|Companies Covered:||Amyndas Pharmaceuticals LLC, Angion, Bolder Biotechnology, Opsona Therapeutics Ltd., Pharming Group NV, Prolong Pharmaceuticals, Prothix BV, Stealth BioTherapeutics, Inc., Zealand Pharma A/S, Faraday Pharmaceuticals, SBI Pharmaceuticals, Omeros Corporations, Orexo AB, Pledpharma AB, Proteo|
|Pitfalls & Challenges:||Due to the increasing number of COVID-19 cases|
Get more details on this report -
The market is witnessing relatively moderate growth due to advancements in technology and the development of new and effective therapies presents significant opportunities for manufacturers in the market. Moreover, government initiatives and funding for research & development of new therapies support market development. Rising R&D activities, and growing demand for advanced therapies. Also, the global ischemia reperfusion injury market is driven by an increase in the prevalence of cardiovascular diseases, the rising number of tissue damage cases, the increase in the geriatric population, and a surge in awareness about ischemia reperfusion injuries among healthcare professionals and patients. Furthermore, growing the expenditure by the key market players for research & development for novel treatment of ischemia reperfusion can enhance the growth of market.
Major factors that restrain the growth of the global ischemia reperfusion injury market during the forecast period due to the high cost of the treatments and therapies in the ischemia reperfusion injury. Moreover, the risk involved in the ischemia reperfusion treatment can also restrain the growth factor over the year.
In 2021, the heart injury segment is dominating the market with the largest market share of 42.31% over the forecast period.
Based on injury type, the global ischemia reperfusion injury market is segmented into heart injury, kidney, injury, intestine injury, and other injuries. Among these, heart injury is dominating the market over the forecast period due to it being a common type of ischemia reperfusion, and across the world, as heart attack is the leading cause of death and disabilities. Moreover, advances in technology such as the development of new drugs and procedures for treating heart attacks, are anticipated to enhance the heart injury segment during the forecast period.
The Hospital segment is dominating the market over the forecast period.
Based on the end users, the global ischemia reperfusion injury market is segmented into hospitals, clinics, ambulatory services, and nursing homes. Among these, the hospital segment is dominating the market over the forecast period due to the rising investment in the hospital sector, particularly in emerging countries, which is boosting the number of hospitals. Also, rising awareness about ischemia reperfusion injuries among healthcare professionals and patients.
Regional Segment Analysis of the global ischemia reperfusion injury market
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Rest of APAC)
- South America (Brazil and the Rest of South America)
- The Middle East and Africa (UAE, South Africa, Rest of MEA)
North America is dominating the market with the largest market share during the forecast period
Get more details on this report -
The North America Market considered for the majority of the share in the global ischemia reperfusion market due to the increasing focus on market key player’s research & development, and moreover, getting the approval from FDA. Additionally, well-established healthcare infrastructure empowers early diagnosis and treatment and High healthcare expenditure also contributes to the growth of the market, as patients have access to advanced technologies and treatment in North America during the forecast period.
Asia Pacific is also expected second leading region with the largest market share growth of ischemia reperfusion due to the increasing geriatric population and also the increasing awareness in the healthcare profession and the general public of the Asia Pacific Region. Furthermore, the increasing number of surgical procedures and increasing focus on organ transplantation also drive market growth in the Asia Pacific during the forecast period.
The report offers the appropriate analysis of the key organizations/companies involved within the Global Ischemia Reperfusion Injury Market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
List of Key Companies
- Amyndas Pharmaceuticals LLC
- Bolder Biotechnology
- Opsona Therapeutics Ltd.
- Pharming Group NV
- Prolong Pharmaceuticals
- Prothix BV
- Stealth BioTherapeutics, Inc.
- Zealand Pharma A/S
- Faraday Pharmaceuticals
- SBI Pharmaceuticals
- Omeros Corporations
- Orexo AB
- Pledpharma AB
Key Target Audience
- Market Players
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
- In March 2022, SBI Pharmaceuticals and the University of Oxford announced that the former initiated a phase II clinical trial to develop a cardioprotective agent combining 5-ALA hydrochloride and the cardiac surgery under cardiopulmonary bypass, the sodium ferrous citrate is response for the mitigation of ischemia reperfusion.
- April 2021, Pharma Drug Announces First FDA Orphan Drug Designation of DMT for the Prevention of Ischemia-Reperfusion Injury from Organ Transplantation.
- In January 2020, Revive Therapeutics Ltd., a cannabis life sciences company, provided an update regarding its clinical development plan for the treatment of liver disorders. The company focus on to increase its product pipeline by exploiting its FDA orphan drug designation for cannabidiol in the prevention of ischemia reperfusion injury from organ transplantation.
This study forecasts revenue at global, regional, and country levels from 2019 to 2030. Spherical Insights has segmented the Global Ischemia Reperfusion Injury Market based on the below-mentioned segments:
Global Ischemia Reperfusion Injury Market, By Injury
- Heart Injury
- Kidney Injury
- Intestine Injury
Global Ischemia Reperfusion Injury Market, By End Users
- Ambulatory Services
- Nursing Home
Global Ischemia Reperfusion Injury Market, Regional Analysis
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Need help to buy this report?